CERS: 64% | Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; Safety Endpoint Of The Proportion Of Patients With Any Related Treatment-Emergent Adverse Events Within 28 Days Of Last Transfusion Was Not Significantly Different For Intercept RBCs
CRNX: 20% | Crinetics Pharmaceuticals shares are trading higher after the company's Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly achieved the primary and all secondary endpoints.
HOTH: 60% | Hoth Therapeutics Says HT-ALZ Emerges As A Promising Novel Solution For Combating Neuroinflammation And Cognitive Deficits Associated With Alzheimer's Disease.